# Processa Pharmaceuticals, Inc.: overview PCSA · Nasdaq · CIK 1533743 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/pcsa.md) · [Financials](/companies/pcsa/financials.md) · [Filings](/companies/pcsa/filings.md) · [Insiders](/companies/pcsa/insiders.md) Latest reported revenue: [$0](/filings/0001493152-23-040472.md) for Q3 FY2023, three months to 2023-09-30, from the 10-Q filed Nov 13, 2023 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-23-040472). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.03)](/filings/0001493152-25-021069.md) | not reported | [(7.58)](/filings/0001493152-26-021721.md) | [(6.26)](/filings/0001493152-26-038334.md) | [(0.07)](/filings/0001493152-25-021069.md) | not reported | [(1.29)](/filings/0001493152-26-021721.md) | [(1.19)](/filings/0001493152-26-038334.md) | | Free cash flow | $k | not reported | [(2,248) d](/filings/0001493152-26-011204.md) | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001493152-22-008156.md) | [0.0](/filings/0001493152-23-009730.md) | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.75)](/filings/0001493152-22-008156.md) | [(34.05)](/filings/0001493152-24-011976.md) | [(8.48)](/filings/0001641172-25-000070.md) | [(96.78)](/filings/0001493152-26-011204.md) | [(10.36)](/filings/0001493152-26-011204.md) | | Free cash flow | $m | not reported | not reported | [(8.1)](/filings/0001641172-25-000070.md) | [(11.2)](/filings/0001493152-26-011204.md) | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pcsa/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Connective Capital Management, LLC](/funds/1543568.md) | 2026-06-30 | $163.7k | 85,274 | | Added +14,538 | | [Stonepine Capital Management, LLC](/funds/1440771.md) | 2026-06-30 | $105.6k | 55,000 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $42.4k | 22,090 | | Reduced −2,818 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $40.9k | 21,306 | | New +21,306 | | [StoneX Group Inc.](/funds/913760.md) | 2026-06-30 | $29.6k | 11,437 | | New +11,437 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $25.5k | 13,292 | | New +13,292 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $25.5k | 13,264 | | New +13,264 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $24.4k | 12,729 | | Unchanged | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $20.8k | 10,857 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $15.0k | 7,794 | | Added +5,263 | ## Recent filings [All 700 filings](/companies/pcsa/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 16:37 ET | [DEF 14A](/filings/0001140361-26-040520.md) | Proxy statement, period 2026-11-30 | 0001140361-26-040520 | | 2026-10-05 | 07:21 ET | [8-K/A](/filings/0001140361-26-038535.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-038535 | | 2026-08-14 | 16:06 ET | [10-Q](/filings/0001493152-26-038334.md) | Quarterly report, period 2026-06-30 | 0001493152-26-038334 | | 2026-08-04 | 17:25 ET | [8-K](/filings/0001493152-26-036032.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-036032 | | 2026-07-29 | 07:35 ET | [8-K](/filings/0001493152-26-035099.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-035099 | | 2026-06-18 | 16:05 ET | [DEF 14A](/filings/0001493152-26-029326.md) | Proxy statement, period 2026-06-18 | 0001493152-26-029326 | | 2026-05-07 | 16:18 ET | [10-Q](/filings/0001493152-26-021721.md) | Quarterly report, period 2026-03-31 | 0001493152-26-021721 | | 2026-04-30 | 17:14 ET | [10-K/A](/filings/0001493152-26-020731.md) | Annual report, amended, period 2025-12-31 | 0001493152-26-020731 | | 2026-04-30 | 17:11 ET | [8-K](/filings/0001493152-26-020728.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-020728 | | 2026-03-18 | 16:05 ET | [10-K](/filings/0001493152-26-011204.md) | Annual report, period 2025-12-31 | 0001493152-26-011204 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-011204.md), filed Mar 18, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1533743 - Tickers: PCSA - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 08:47 ET. No prices; not investment advice.